The best approach to cancer therapy is to focus on the commonalities shared by all cancer. At the moment that means lengthening of telomeres. Every cancer does it. If you can suppress telomerase and ALT (alternative lengthening of telomeres), or if you can reliably identify the biochemistry of cells abusing telomerase and ALT, then you can kill any cancer.<p>E.g. a universal cancer vaccine based on this approach: <a href="http:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC4471666&#x2F;" rel="nofollow">http:&#x2F;&#x2F;www.ncbi.nlm.nih.gov&#x2F;pmc&#x2F;articles&#x2F;PMC4471666&#x2F;</a><p>E.g. disable part of the mechanism by which telomerase lengthens telomeres: <a href="http:&#x2F;&#x2F;www.eurekalert.org&#x2F;pub_releases&#x2F;2015-05&#x2F;cndi-csa051115.php" rel="nofollow">http:&#x2F;&#x2F;www.eurekalert.org&#x2F;pub_releases&#x2F;2015-05&#x2F;cndi-csa05111...</a><p>People such as the SENS folk have been advocating this approach for more than a decade, but the research community is slow in adopting it. The vast majority of cancer research continues to be a matter of doing very expensive things that only work for one tiny subtype of cancer. If we&#x27;re doing expensive things, then they should be efficient expensive things.